scholarly journals Noninvasive prenatal testing by maternal plasma DNA analysis: Current practice and future applications

2014 ◽  
Vol 74 (sup244) ◽  
pp. 48-53 ◽  
Author(s):  
Rossa W. K. Chiu
Keyword(s):  
Current Practice ◽  
Dna Analysis ◽  
Prenatal Testing ◽  
Maternal Plasma ◽  
Plasma Dna ◽  
Noninvasive Prenatal Testing

scholarly journals Noninvasive Prenatal Testing by Nanopore Sequencing of Maternal Plasma DNA: Feasibility Assessment

2015 ◽  
Vol 61 (10) ◽  
pp. 1305-1306 ◽  
Author(s):  
Suk Hang Cheng ◽  
Peiyong Jiang ◽  
Kun Sun ◽  
Yvonne K Y Cheng ◽  
K C Allen Chan ◽  
...  
Keyword(s):  
Prenatal Testing ◽  
Maternal Plasma ◽  
Nanopore Sequencing ◽  
Plasma Dna ◽  
Noninvasive Prenatal Testing ◽  
Feasibility Assessment

scholarly journals Universal Haplotype-Based Noninvasive Prenatal Testing for Single Gene Diseases

2017 ◽  
Vol 63 (2) ◽  
pp. 513-524 ◽  
Author(s):  
Winnie W I Hui ◽  
Peiyong Jiang ◽  
Yu K Tong ◽  
Wing-Shan Lee ◽  
Yvonne K Y Cheng ◽  
...  
Keyword(s):  
Single Gene ◽  
Family Members ◽  
Prenatal Testing ◽  
Maternal Plasma ◽  
Nucleotide Polymorphisms ◽  
Plasma Dna ◽  
Sequencing Technology ◽  
Noninvasive Prenatal Testing ◽  
Haplotype Phasing ◽  
Mutational Status

Abstract BACKGROUND Researchers have developed approaches for the noninvasive prenatal testing of single gene diseases. One approach that allows for the noninvasive assessment of both maternally and paternally inherited mutations involves the analysis of single nucleotide polymorphisms (SNPs) in maternal plasma DNA with reference to parental haplotype information. In the past, parental haplotypes were resolved by complex experimental methods or inferential approaches, such as through the analysis of DNA from other affected family members. Recently, microfluidics-based linked-read sequencing technology has become available and allows the direct haplotype phasing of the whole genome rapidly. We explored the feasibility of applying this direct haplotyping technology in noninvasive prenatal testing. METHODS We first resolved the haplotypes of parental genomes with the use of linked-read sequencing technology. Then, we identified SNPs within and flanking the genes of interest in maternal plasma DNA by targeted sequencing. Finally, we applied relative haplotype dosage analysis to deduce the mutation inheritance status of the fetus. RESULTS Haplotype phasing and relative haplotype dosage analysis of 12 out of 13 families were successfully achieved. The mutational status of these 12 fetuses was correctly classified. CONCLUSIONS High-throughput linked-read sequencing followed by maternal plasma-based relative haplotype dosage analysis represents a streamlined approach for noninvasive prenatal testing of inherited single gene diseases. The approach bypasses the need for mutation-specific assays and is not dependent on the availability of DNA from other affected family members. Thus, the approach is universally applicable to pregnancies at risk for the inheritance of a single gene disease.

Recent Advances in the Noninvasive Prenatal Testing for Chromosomal Abnormalities Using Maternal Plasma DNA

2020 ◽  
Vol 7 (1) ◽  
pp. 17-23 ◽  
Author(s):  
Tze Kin Lau ◽  
Xiaofan Zhu ◽  
Yvonne Ka Yin Kwok ◽  
Tak Yeung Leung ◽  
Kwong Wai Choy
Keyword(s):  
Chromosomal Abnormalities ◽  
Prenatal Testing ◽  
Maternal Plasma ◽  
Plasma Dna ◽  
Noninvasive Prenatal Testing ◽  
Recent Advances

scholarly journals Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples

2013 ◽  
Vol 33 (6) ◽  
pp. 569-574 ◽  
Author(s):  
Tracy Futch ◽  
John Spinosa ◽  
Sucheta Bhatt ◽  
Eileen Feo ◽  
Richard P. Rava ◽  
...  
Keyword(s):  
Clinical Laboratory ◽  
Prenatal Testing ◽  
Maternal Plasma ◽  
Plasma Dna ◽  
Noninvasive Prenatal Testing ◽  
Laboratory Experience ◽  
Fetal Aneuploidy

Noninvasive prenatal testing for fetal trisomy 9 mosaicism by maternal plasma DNA sequencing

2015 ◽  
Vol 4 (1) ◽  
Author(s):  
Luming Sun ◽  
Lei Zhang ◽  
Jia Zhou ◽  
Xiaonan Yang ◽  
Tao Duan ◽  
...  
Keyword(s):  
Dna Sequencing ◽  
Trisomy 21 ◽  
Prenatal Screening ◽  
Detection Efficiency ◽  
Prenatal Testing ◽  
Maternal Plasma ◽  
Plasma Dna ◽  
Noninvasive Prenatal Testing ◽  
Trisomy 9 ◽  
Screening And Diagnosis

AbstractMaternal plasma DNA sequencing based noninvasive prenatal testing (NIPT) has been proven to be highly accurate in the detection of trisomy 21, 18, 13, X and Y, however, few reports have been made on its detection efficiency of rare complex aneuploidies. Here, we report a case of fetal trisomy 9 mosaicism identified by using NIPT, which may provide useful information for the further integration of NIPT into prenatal screening and diagnosis practice.

scholarly journals Combined Count- and Size-Based Analysis of Maternal Plasma DNA for Noninvasive Prenatal Detection of Fetal Subchromosomal Aberrations Facilitates Elucidation of the Fetal and/or Maternal Origin of the Aberrations

2017 ◽  
Vol 63 (2) ◽  
pp. 495-502 ◽  
Author(s):  
Stephanie C Y Yu ◽  
Peiyong Jiang ◽  
K C Allen Chan ◽  
Brigitte H W Faas ◽  
Kwong W Choy ◽  
...  
Keyword(s):  
Massively Parallel Sequencing ◽  
Prenatal Testing ◽  
Maternal Plasma ◽  
Massively Parallel ◽  
Test Cases ◽  
Plasma Dna ◽  
Diagnostic Specificity ◽  
Noninvasive Prenatal Testing ◽  
Prenatal Detection ◽  
Positive Results

Abstract BACKGROUND Noninvasive prenatal detection of fetal subchromosomal copy number aberrations (CNAs) can be achieved through massively parallel sequencing of maternal plasma DNA. However, when a mother herself is a carrier of a CNA, one cannot discern if her fetus has inherited the CNA. In addition, false-positive results would become more prevalent when more subchromosomal regions are analyzed. METHODS We used a strategy that combined count- and size-based analyses of maternal plasma DNA for the detection of fetal subchromosomal CNAs in 7 target regions for 10 test cases. RESULTS For the 5 cases in which CNAs were present only in the fetus, the size-based approach confirmed the aberrations detected by the count-based approach. For the 5 cases in which the mother herself carried an aberration, we successfully deduced that 3 of the fetuses had inherited the aberrations and that the other 2 fetuses had not inherited the aberrations. No false positives were observed in this cohort. CONCLUSIONS Combined count- and size-based analysis of maternal plasma DNA permits the noninvasive elucidation of whether a fetus has inherited a CNA from its mother who herself is a carrier of the CNA. This strategy has the potential to improve the diagnostic specificity of noninvasive prenatal testing.

scholarly journals Detection of fetal trisomy 9 mosaicism by noninvasive prenatal testing through maternal plasma DNA sequencing

2018 ◽  
Vol 57 (4) ◽  
pp. 594-597 ◽  
Author(s):  
Chung-Yuan Lee ◽  
Hsing-Ju Su ◽  
Yu-Tzu Cheng ◽  
Yu-Lun Ku ◽  
Yeh Giin Ngo ◽  
...  
Keyword(s):  
Dna Sequencing ◽  
Prenatal Testing ◽  
Maternal Plasma ◽  
Plasma Dna ◽  
Noninvasive Prenatal Testing ◽  
Trisomy 9

scholarly journals Noninvasive Prenatal Testing of Methylmalonic Acidemia cblC Type Using the cSMART Assay for MMACHC Gene Mutations

2022 ◽  
Vol 12 ◽  
Author(s):  
Weigang Lv ◽  
Lili Liang ◽  
Xin Chen ◽  
Zhuo Li ◽  
Desheng Liang ◽  
...  
Keyword(s):  
Prenatal Diagnosis ◽  
Sensitivity And Specificity ◽  
Single Molecule ◽  
Gene Mutations ◽  
Prenatal Testing ◽  
Maternal Plasma ◽  
Methylmalonic Acidemia ◽  
Plasma Dna ◽  
Noninvasive Prenatal Testing ◽  
Monogenic Diseases

Noninvasive prenatal testing (NIPT) for monogenic disorders has been developed in recent years; however, there are still significant technical and analytical challenges for clinical use. The clinical feasibility of NIPT for methylmalonic acidemia cblC type (cblC type MMA) was investigated using our circulating single-molecule amplification and re-sequencing technology (cSMART). Trios molecular diagnosis was performed in 29 cblC type MMA-affected children and their parents by traditional Sanger sequencing. In the second pregnancy, invasive prenatal diagnosis (IPD) of the pathogenic MMACHC gene was used to determine fetal genotypes, and NIPT was performed using a novel MMACHC gene–specific cSMART assay. Maternal–fetal genotypes were deduced based on the mutation ratio in maternal plasma DNA. Concordance of fetal genotypes between IPD and NIPT, and the sensitivity and specificity of NIPT were determined. After removing two cases with a low P value or reads, the concordance ratio for NIPT and IPD was 100.00% (27/27), and the sensitivity and specificity were 100.00% (54.07–100.00%) and 100.00% (83.89–100.00%), respectively. This study demonstrates that NIPT using the cSMART assay for cblC type MMA was accurate in detecting fetal genotypes. cSMART has a potential clinical application as a prenatal diagnosis and screening tool for carrier and low-risk genotypes of cblC type MMA and other monogenic diseases.

Sign in / Sign up

Export Citation Format

Share Document